Cure Parkinson’s and Alzheimer’s Research UK announce a partnership  

Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. 

There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach.    

We are recognising the overlap in underlying biological processes and drugs that may show potential therapeutic benefits for both Parkinson’s and the diseases that cause dementia. This partnership will capitalise on shared research findings, expertise and resources to accelerate drug development for both conditions. 

 This partnership is part of Alzheimer’s Research UK’s Clinical Accelerator programme. This initiative hopes to improve the UK’s ability to run clinical trials for dementia by providing funding for innovative trials and researchers, reducing the time it takes for promising treatments to reach those affected by dementia.  

It is also an extension to Cure Parkinson’s International Linked Clinical Trials (iLCT) programme, led in partnership with the Van Andel Institute. It is an initiative which has an established track record for advancing clinical trials. In June 2025 the iLCT committee meeting will host a joint session where drugs identified as having potential to be repurposed or repositioned for the mutual benefit of dementia and Parkinson’s will be reviewed. This review is carried out by a panel of international experts.   

We hope that this partnership will serve as a template for future cross-condition collaborations, for example with multiple sclerosis, where both conditions are influenced by inflammation.  

We are delighted to announce Cure Parkinson’s partnership with Alzheimer’s Research UK around our International Linked Clinical Trials Initiative.  We are confident it will accelerate finding treatments with the potential to slow, stop or reverse Parkinson’s as it means we can investigate drugs of mutual interest, targeting aspects of biology of both conditions.  This partnership will also capitalise on shared research findings, expertise and resources to speed up drug development for both conditions.”

Helen Matthews, CEO, Cure Parkinson’s